Search Clinical Trials
Active, Not Recruiting
3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN (External Link)
We will make iC9-GD2 T cells by infecting normal T cells with a retroviral vector containing the iC9-GD2 gene. After the new gene has been put into the T cells, …
Baylor Role:
Lead Sponsor
Terminated
Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme (External Link)
To generate CMV-T cells we put a specially produced carrier virus (adenovirus) that carries one CMV gene into the patient's blood monocytes or dendritic cells. These cells are then used …
Baylor Role:
Lead Sponsor
Completed
CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM (External Link)
When the patient enrolls on this study, they will be assigned to a dose of HER2-CAR CMV-T cells. The patient will be given a single injection of cells into the …
Baylor Role:
Lead Sponsor
Active, Not Recruiting
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma (External Link)
WHAT IS THE OVERALL TREATMENT PLAN AND HOW MANY VACCINATIONS WILL THE PATIENT RECEIVE? There will be several injections of the vaccine scheduled. The first injection will be given 3 …
Baylor Role:
Lead Sponsor
Completed
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma (External Link)
With the exception of patients with diffuse intrinsic pontine glioma (DIPG), all patients should have the maximal surgical resection that can be safely performed prior to study entry. Submission of …
Baylor Role:
Lead Sponsor
Active, Not Recruiting
A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells (External Link)
TREATMENT PLAN: Standard Chemotherapy for Neuroblastoma: Standard therapy for neuroblastoma is given in 3 phases: induction, consolidation, and maintenance. For enrollment in this vaccine study patients and their physicians must …
Baylor Role:
Lead Sponsor
Completed
Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma (External Link)
Induction Phase Overview The induction phase is approximately 15 weeks long. Chemotherapy is generally given every 3 weeks, each 3 week block is called a "cycle". During these 15 weeks …
Baylor Role:
Lead Sponsor
Completed
Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement (External Link)
Zoledronic Acid (Zometa), a new generation, highly potent bisphosphonate used to treat osteoporosis and hypercalcemia of malignancy, is widely used in adult malignancies with potential for bone metastasis such as …
Baylor Role:
Lead Sponsor
Completed
Subtotal Resection of Large Acoustic Neuromas With Possible Stereotactic Radiation Therapy (External Link)
The current standard treatment of a large tumor of the balance nerve (acoustic neuroma or vestibular schwannoma) is surgical resection. Complete removal of such tumor is associated with significant risks …
Baylor Role:
Collaborator
Active, Not Recruiting
Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients (External Link)
Earlier, the patient gave us blood to make 14g2a chimeric receptor-T cells and 14g2a chimeric receptor-EBV CTLs in the laboratory. These cells were grown and frozen for the patient. The …
Baylor Role:
Lead Sponsor